Stock Market News
Shire reports good start to 2018 as Takeda deal beckons
(WebFG News) - Shire, which is in talks to be bought by Japan's Takeda Pharmaceutical, said it made a good start to 2018 as sales rose in the first quarter.
The biotechnology company said product sales in the three months to the end of March increased 7% to $3.6bn (£2.6bn). The increase was driven a 10% increase to $2.7bn in sales of treatments for rare diseases in fields such as immunology and haematology. Neuroscience sales fell 2% to $918m.
The Dublin-based FTSE 100 company said it also had a strong pipeline of new treatments. Shire's business has attracted the attention of Takeda, which has made several approaches to buy the company to freshen up its pipeline.
On 25 April Shire said its board was willing to recommend Takeda's fifth proposal to shareholders subject to ironing out terms. The Japanese company's indicative offer values Shire at £46bn.
Flemming Ornskov, Shire's chief executive, said: "Shire is off to a good start in 2018, delivering on our key priorities of commercial execution, pipeline progression, debt pay down, and portfolio optimisation."
Shire reduced its net debt by $866m to $18.2bn in the quarter. The company agreed on 16 April to sell its oncology business to Servier for $2.4bn.
The biotechnology company said product sales in the three months to the end of March increased 7% to $3.6bn (£2.6bn). The increase was driven a 10% increase to $2.7bn in sales of treatments for rare diseases in fields such as immunology and haematology. Neuroscience sales fell 2% to $918m.
The Dublin-based FTSE 100 company said it also had a strong pipeline of new treatments. Shire's business has attracted the attention of Takeda, which has made several approaches to buy the company to freshen up its pipeline.
On 25 April Shire said its board was willing to recommend Takeda's fifth proposal to shareholders subject to ironing out terms. The Japanese company's indicative offer values Shire at £46bn.
Flemming Ornskov, Shire's chief executive, said: "Shire is off to a good start in 2018, delivering on our key priorities of commercial execution, pipeline progression, debt pay down, and portfolio optimisation."
Shire reduced its net debt by $866m to $18.2bn in the quarter. The company agreed on 16 April to sell its oncology business to Servier for $2.4bn.
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price